IL212962A0 - Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases - Google Patents
Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseasesInfo
- Publication number
- IL212962A0 IL212962A0 IL212962A IL21296211A IL212962A0 IL 212962 A0 IL212962 A0 IL 212962A0 IL 212962 A IL212962 A IL 212962A IL 21296211 A IL21296211 A IL 21296211A IL 212962 A0 IL212962 A0 IL 212962A0
- Authority
- IL
- Israel
- Prior art keywords
- modulation
- treatment
- autoimmune diseases
- inflammatory response
- chronic inflammatory
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 101150081923 IL4 gene Proteins 0.000 title 1
- 230000012085 chronic inflammatory response Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801601 | 2008-11-17 | ||
| PCT/DK2009/050304 WO2010054667A1 (en) | 2008-11-17 | 2009-11-17 | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL212962A0 true IL212962A0 (en) | 2011-07-31 |
Family
ID=41510516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL212962A IL212962A0 (en) | 2008-11-17 | 2011-05-17 | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8546321B2 (OSRAM) |
| EP (1) | EP2365983B1 (OSRAM) |
| JP (1) | JP5750373B2 (OSRAM) |
| CN (1) | CN102216323B (OSRAM) |
| AU (1) | AU2009316076B2 (OSRAM) |
| BR (1) | BRPI0921717A2 (OSRAM) |
| CA (1) | CA2743394C (OSRAM) |
| ES (1) | ES2620437T3 (OSRAM) |
| IL (1) | IL212962A0 (OSRAM) |
| NZ (1) | NZ592943A (OSRAM) |
| RU (1) | RU2542375C2 (OSRAM) |
| WO (1) | WO2010054667A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2989085T3 (es) | 2011-01-18 | 2024-11-25 | Bioniz Therapeutics Inc | Composiciones para modular la actividad de citoquinas gamma-c |
| US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
| RU2736732C2 (ru) | 2015-04-02 | 2020-11-19 | Интервет Интернэшнл Б.В. | Антитела к альфа-рецептору собачьего интерлейкина-4 |
| DK3359556T3 (en) | 2015-10-09 | 2021-08-30 | Bioniz Llc | Modulering af gamma-c-cytokinaktivitet |
| JP7752929B2 (ja) * | 2017-04-07 | 2025-10-14 | バイオニズ セラピューティクス インコーポレイテッド | γｃサイトカイン活性の安定な調節剤 |
| KR102095284B1 (ko) | 2017-05-11 | 2020-04-01 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
| ES2971898T3 (es) | 2018-02-27 | 2024-06-10 | Univ Der Johannes Gutenberg Univ Mainz | Nuevos compuestos peptídicos obtenidos a partir de IL-4-/IL-13 para el tratamiento o la prevención de enfermeda-des neurodegenerativas o neuroinflamatorias |
| CN111494626B (zh) * | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
| EP3976182A4 (en) | 2019-05-03 | 2023-01-18 | Bioniz, LLC | MODULATION OF THE EFFECTS OF GAMMA CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS |
| ES3032223T3 (en) | 2022-01-05 | 2025-07-16 | Serodus Aps | Il-4 derived peptides for use in the treatment of obesity |
| WO2023209186A1 (en) | 2022-04-29 | 2023-11-02 | Serodus Aps | Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05503088A (ja) * | 1989-11-21 | 1993-05-27 | ザ ユニバーシティー オブ メルボルン | 抗炎症用の組成物及び方法 |
| ES2085983T3 (es) * | 1989-12-20 | 1996-06-16 | Schering Corp | Antagonistas de anticuerpos de la interleuquina-4 humana. |
| US6337072B1 (en) * | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| ATE412433T1 (de) * | 1999-02-12 | 2008-11-15 | Scripps Research Inst | Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| US20030056244A1 (en) * | 2000-05-02 | 2003-03-20 | Ning Huang | Feed additive compositions and methods |
| FR2838444B1 (fr) * | 2002-04-10 | 2016-01-01 | Neovacs | Nouveaux peptides et leur application en therapeutique |
| WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
| JP2007537989A (ja) * | 2003-10-16 | 2007-12-27 | アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 安定化ペプチド |
-
2009
- 2009-11-17 BR BRPI0921717A patent/BRPI0921717A2/pt not_active IP Right Cessation
- 2009-11-17 RU RU2011121971/10A patent/RU2542375C2/ru not_active IP Right Cessation
- 2009-11-17 CA CA2743394A patent/CA2743394C/en active Active
- 2009-11-17 EP EP09764175.7A patent/EP2365983B1/en active Active
- 2009-11-17 AU AU2009316076A patent/AU2009316076B2/en not_active Ceased
- 2009-11-17 CN CN200980145907.4A patent/CN102216323B/zh not_active Expired - Fee Related
- 2009-11-17 US US13/127,574 patent/US8546321B2/en active Active
- 2009-11-17 WO PCT/DK2009/050304 patent/WO2010054667A1/en not_active Ceased
- 2009-11-17 NZ NZ592943A patent/NZ592943A/xx not_active IP Right Cessation
- 2009-11-17 ES ES09764175.7T patent/ES2620437T3/es active Active
- 2009-11-17 JP JP2011535880A patent/JP5750373B2/ja active Active
-
2011
- 2011-05-17 IL IL212962A patent/IL212962A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011121971A (ru) | 2012-12-27 |
| US20110300148A1 (en) | 2011-12-08 |
| CN102216323B (zh) | 2016-08-03 |
| JP2012508698A (ja) | 2012-04-12 |
| US8546321B2 (en) | 2013-10-01 |
| CA2743394C (en) | 2018-01-02 |
| WO2010054667A1 (en) | 2010-05-20 |
| ES2620437T3 (es) | 2017-06-28 |
| EP2365983A1 (en) | 2011-09-21 |
| RU2542375C2 (ru) | 2015-02-20 |
| NZ592943A (en) | 2012-09-28 |
| CA2743394A1 (en) | 2010-05-20 |
| BRPI0921717A2 (pt) | 2018-10-09 |
| CN102216323A (zh) | 2011-10-12 |
| EP2365983B1 (en) | 2016-12-28 |
| AU2009316076A1 (en) | 2010-05-20 |
| AU2009316076B2 (en) | 2015-11-19 |
| JP5750373B2 (ja) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL212962A0 (en) | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases | |
| IL210810B (en) | Peptides to treat pain and/or inflammation | |
| IL259547B (en) | Isolated protein and preparations containing it for use in the treatment of disorders caused by il-1 | |
| ZA201100974B (en) | Treatment of autoimmune and inflammatory disease | |
| ZA200707591B (en) | Dihyrothienopyrimidines for the treatment of inflammatory diseases | |
| IL211930A (en) | Peptides and nonsense for their use in preventing cell adhesion | |
| IL223667B (en) | 4a100s antibodies and medical uses thereof | |
| PL2496596T3 (pl) | Peptydy terapeutyczne | |
| GB0904044D0 (en) | The treatment of inflammatory disorders and pain | |
| IL241253A0 (en) | Peptides for the treatment of neurodegenerative diseases | |
| ZA200908989B (en) | Enhancement of the efficacy of therapeutic proteins | |
| GB2460181B (en) | Depsipeptides and their therapeutic use | |
| GB2460178B (en) | Depsipeptides and their therapeutic use | |
| IL216199A (en) | A peptide containing the sequence ednimvtfrnqasr | |
| ZA201100019B (en) | Variant hhip1 protein and methods and uses thereof | |
| GB0724953D0 (en) | Methods of peptide modification | |
| SI2555790T1 (sl) | Terapevtska uporaba proteina beta2-mikroglobulina | |
| EP2254901A4 (en) | THERAPEUTIC PEPTIDES | |
| GB2460180B (en) | Depsipeptides and their therapeutic use | |
| HK1152532A (en) | Treatment of autoimmune and inflammatory disease | |
| GB0803397D0 (en) | The treatment of inflammatory disorders and pain | |
| GB0817330D0 (en) | The treatment of inflammatory disorders and pain | |
| GB0820986D0 (en) | The treatment of inflammatory disorder and pain | |
| GB0809319D0 (en) | The treatment of puritus | |
| AU2008900848A0 (en) | Therapeutic peptides |